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Rat neonatal heart muscle cells (cardiomyocytes) were found to express a high-affinity surface receptor for transforming growth factor-j?2 (TGF-p2). 
Specific bmding was rapid, saturable, ligand-selective, and reversible. Equilibrium binding analyses revealed that the cardiomyocyte had one class 
of specific binding sites with a Kd % 26 pM TGF-/32, a B,,,,, of -9 fmol/106 cells, and -5,000 binding sites/cardiomyocyte. Binding was selective 
for TGF,B2 in comparison to other TGF,B isoforms and to unrelated growth factors. Affinity-binding experiments revealed three types of 
cardiomyocyte TGF-/?2 binding proteins, the most promment of which corresponded to the high-molecular mass proteoglycan. These data raise 
the possibility that the anti-ischemic cardioprotective effects of TGF-/3 may reflect receptor-mediated signal transduction at the cardiomyocyte level. 
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1. INTRODUCTION 
The peptide cytokine transforming growth factor-/? 
(TGF-B) exists as a family of three highly conserved 
mammalian isoforms (TGF-Pl, -/I2, and $3) with sig- 
nificant (-70%) sequence homology and structural sim- 
ilarity [l]. Although initially described in transformed 
cells, TGF-P is synthesized in many tissues. The multi- 
ple effects of TGF-p on target cells are mediated by 
specific, high-affinity TGF,B receptors, the binding to 
which is the first step in a poorly understood signal- 
transduction cascade [2]. The distribution and charac- 
teristics of cellular TGF-/I receptors are, consequently, 
topics of great current interest [2]. 
tion [4], endothelial preservation [5], and/or an antioxi- 
dant effect [6], detailed knowledge of TGF-P’s physiol- 
ogy in normal, let alone ischemic, heart muscle is lack- 
ing. A direct relationship between cardiomyocyte injury 
and TGF-/I is implied by the changes in myocardial 
TGF-/I content/gene expression during ischemia and 
post-ischemic reperfusion [3]. 
The cardiovascular system is both a source of TGF-p 
and a site of action of this cytokine. TGF-p has been 
detected in the vessel wall, circulating blood cells, and 
heart muscle [3]. Cardiomyocytes secrete TGF-/I which 
can associate with the cellular membrane [4]. One of the 
most important cardiovascular aspects of TGF-/? is its 
salutary effects against myocardial ischemia 151. Al- 
though the anti-ischemic cardioprotection has been hy- 
pothesized to reflect support of heart muscle contrac- 
As detailed in a recent review [7]. little direct informa- 
tion is available regarding cardiomyocytes as peptide 
growth factor targets. We report the initial identifica- 
tion and characterization of a specific receptor popula- 
tion responsible for TGF;02 binding to neonatal rat 
cardiomyocytes. Our results constitute the first bio- 
chemical analysis of cardiomyocyte TGF-/3 receptors 
and provide a context for potential TGF-P2 signal 
transduction in heart muscle. 
2. MATERIALS AND METHODS 
2.1. Matenals 
Correspondence address. D.R. Janero, CIBA-GEIGY Pharmaceuti- 
cals, 556 Morris Avenue, Bldg. V, Room 144. Summit, NJ 07901, 
USA. Fax: (1) (908) 277-4756. 
Abbrermtions: aFGF, acidic fibroblast growth factor: BME, Eagle’s 
basal medium: BSA, bovine serum albumin: DSS, disuccinimidyl 
suberate: EDTA, ethylene diammetetraacettc acid; HEPES, N-2-hy- 
droxyethylpiperazine-N’-2-ethanesulfomc acid: PDGF. platelet de- 
rived growth factor; PMSF, phenylmethanesulfonyl Auoride; TGF,O, 
transforming growth factor-/I; Trts, tris(hydroxymethyl)amino- 
methane. 
Bovine serum albumin, essentially fatty acid-free (BSA), N-2-hy- 
droxyethylpiperazme-N’-2-ethanesulfomc acid (HEPES), tris(hydrox- 
ymethyl)aminomethane (Tris). ethylene diaminetetraacetic acid 
(EDTA). protease inhibitors, and miscellaneous biochemicals were 
obtained at the highest available grade from Sigma (St. Louis, MO). 
Protease inhibitor cocktail I was an aqueous solution of 1 mg/ml 
leupeptin, 1 mg/ml antipam. 5 mg/ml aprotinin, 10 mglml soybean 
trypsin inhibitor, and 10 mg/ml benzamidine hydrochloride. Protease 
inhibitor cocktail II consisted of 1 mg/ml pepstatin, 1 mg/ml bestatin, 
and 30 mM phenylmethanesulfonyl fluoride (PMSF) in dimethyl- 
sulfoxide. Disuccmimidyl suberate (DSS) was from Pierce Chemical 
Co. (Rockford, IL). [‘151]TGF-/?2 (1,800-2,200 Cilmmol, spec. act.) 
was a human recombinant product [8] iodinated as detailed [9]. 
Human recombinant TGF-/33 was provided by N. Cerlettt (CIBA- 
GEIGY, Basel, Switzerland). TGF-/Jl and platelet-derived growth 
factor (PDGF) were from human platelets, and acidic fibroblast 
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growth factor (aFGF) was from bovme bram (R & D Systems. Min- 
neapohs. MN) 
Hearts were obtained from 3-day-old SpragueeDawley rats, and 
cardiomyocytes were isolated by external digestion of left-ventricular 
myocardium [I 0,l I]. The isolated cardiomyocytes were seeded in com- 
plete Eagle’s basal medium (BME) (5 x 10’ tells/35-mm well) and 
incubated at 37°C under 95% air/58 CO- [lo]. Confluency was 
reached within 72 h post-plating. at which t;me the cells were used 
experimentally as a monolayer network of synchronously beating car- 
diomyocytes containing 109 f 5 pg cell protem/well (mean ? SD.: 
N = 10). The experimental cultures consisted almost exclusively 
(>95%) of ventricular cardiomyocytes [I I]. 
2.3 Equdlbtmm bmdmg studm 
Cardtomyocyte monolayers were preincubated overnight (i.e. for 18 
h) m serum-free medium: the duration of the serum-free preincubation 
(from 3 to 24 h) did not alter the subsequent [“‘I]TGF-B2 binding 
(data not shown). The monolayers were then washed with 6 ml Ice-cold 
bmding buffer (serum-free BME: 0.1% (w/v) BSA. 25 mM HEPES, pH 
7.4) Each washed monolayer was incubated with [“‘I]TGF#2 m 1 .O 
ml ice-cold binding buffer at 3’C with contmuous gentle agitation. 
The concentrations of [‘“IITGF-p2 used and the incubation times 
were as indicated in the text and figure legends. The binding assay was 
terminated by removing the [“51]TGF-~2-contammg bmding buffer 
and washing each labeled monolayer with 6 ml ice-cold binding buffer. 
The cells were then solubilized with 0.6 ml solubihzatton buffer (20 
mM HEPES. pH 7.3, 1% (v/v) Triton X-100. 10% (v/v) glycerol, 0 01% 
(w/v) BSA). and triplicate ahquots were counted for “I label. Non- 
specific binding was taken as the [“SI]TGF-/J2 which became cell- 
associated during the bmdmg assay m the presence of a l.OOO-fold 
molar excess of unlabeled hgand. For competition studies, the bmdmg 
assay was conducted with 40 pM [“51]TGF-P2 in the presence of 
varying concentrations of unlabeled TGF-pl, $2. ;83, PDGF. or 
aFGF. For displacement studies, equihbrmm bmdmg was established 
with 4. 20, or 40 pM [“SI]TGF-/33, and the labeled cardiomyocytes 
were then incubated with a l,OOO-fold molar excess of unlabeled TGF- 
g2 for various periods of time under bmdmg assay conditions. 
Cardiomyocytes were incubated with 40 pM [“51]TGF-~2 for 30 
min and processed as for equilibrium bindmg (above). The washed 
cells were then lysed with hypotomc buffer (5 mM HEPES, 1 mM 
MgSOJ, pH 7.4) and cytoplasmic and membrane fractions were pre- 
pared [I I]. The subcellular fractions were counted for associated “‘I 
label. 
Confluent cardtomyocyte monolayers were Incubated with 
[“‘IITGF;O2 under equilibrium-binding conditions (above) to gener- 
ate a cell monolayer with ligand-occupied TGF;B2 receptors. After 
mcubation with [“‘IITGF-b2, each monolayer was washed with 6.0 ml 
binding buffer and then rinsed with 1.0 ml ice-cold bmdmg buffer 
lacking BSA. The labeled cells were incubated at 4°C for 15 mm with 
BSA-free binding buffer containing 135 PM DSS. Each monolayer 
was then rapidly rinsed wtth 1 .O ml ice-cold detachment buffer (10 mM 
Tris. pH 7.4, 0.25 M sucrose, 1 mM EDTA. 0.3 mM PMSF) and 
harvested mto 1 ml of this buffer supplemented with 10 PI/ml of each 
protease inhibitor cocktail. Samples were solubihzed m buffer (10 mM 
Tris, pH 7.0, 125 mM NaCl. 1 mM EDTA, 1% (v/v) Triton X-100. 10 
@ml of each protease inhibitor cocktail) and prepared for SDS- 
PAGE according to Laemmh [12] on 7% (w/v) polyacrylamide slab 
gels, which were processed for autoradiography as detailed [13]. 
2.6. Data eouluatron 
The ReceptorFit program (London Software. Chagrm Falls, OH) 
[14] was used for progressive-complexity analysis of the binding data 
and for Klotz transformations [15]. The program features weighted 
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non-linear least-squares regression Statistical significance of the data- 
fit to a gtven receptor model was m accordance with F-test criteria at 
P s 0.01, Scatchard [16] and isotherm (i.e. bound vs. free) plots were 
generated with Cricket Software (Malvern, PA). 
3. RESULTS 
We initially assessed the interaction of TGF,02 with 
the cardiomyocyte for characteristics indicative of a 
specific TGF-/?2 receptor by incubating the cells under 
serum-free conditions with selected concentrations of 
[“51]TGF-p2 for 30 min or 40 pM [“51]TGF-/?2 for 
discrete intervals up to 60 min. These experiments re- 
vealed a concentration-dependent association of 
[‘?]TGF-P2 with the cardiomyocyte (Fig. 1). The dif- 
ference between cardiomyocyte-associated [“‘I]TGF$2 
in the absence and presence of a 1 ,OOO-fold molar excess 
of unlabeled TGF-p2 defined a saturable, specific-bind- 
ing component, which plateaued in a time-dependent 
manner (Fig. 1. inset). The plateau did not reflect a 
ligand deficit, for the specifically bound [‘“‘IITGF-/I2 at 
30 min was some l&fold less than that available from 
the 40 pM [‘?]TGF-j73 supplied, and total (i.e. non- 
specific) binding continued to increase after specific 
binding had become saturated. Consequently, pro- 
longed (up to 3 h) binding incubations did not increase 
<I 
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Fig. 1, Concentration- and time-dependence of cardiomyocyte TGF- 
82 bmdmg. Confluent cardiomyocyte monolayers (5 x 10’ cells/well) 
were Incubated for 30 mm at 4°C in binding buffer containmg 2-80 
pM [“‘I]TGF-,82 or for up to 60 min with 40 pM [“SI]TGF-~2 (inset). 
Parallel incubattons were carried out in the presence of a l.OOO-fold 
molar excess of unlabeled TGFj32 to assess non-specific binding. At 
the end of each incubation. the cardiomyocytes were recovered. and 
the cell-associated [rzLI]TGF-@2 was quantified. Specific binding (0) 
represents the calculated difference between total (m) and non-specific 
(c) bmdmg. Data are means + S.E.M. (n z 6 independent cultures). 
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Fig. 2. Scatchard (A) and iterative non-linear least-squares regression 
(B) analyses of concentration-dependent cardtomyocyte TGF-b2 
binding data from experiments of the type depicted m Fig. 1. The 
dashed lines (---) represent regression (A) and non-linear least 
squares (B) fits of the binding data. For B. the total (a) and measured 
non-specific (0) binding data incorporated into the model are dis- 
played. The data are dertved from three independent cultures, each 
value the average over three wells. The range about each mean was 
<lO%. 
specific binding, but resulted in total binding which was 
largely non-specific (data not shown). In accord with 
the propensity of TGF-P to adhere to surfaces [17], 
non-specific binding averaged some 35% of total after 
a 30 min binding assay with 40 pM [“IITGF-b2, a 
proportion observed in other cell types [18]. Under the 
binding conditions employed, cardiomyocyte-associ- 
ated [“‘I]TGF$2 was completely recovered in the par- 
ticulate membrane fraction prepared from a hypotonic 
cell lysate; ligand internalization appeared insignificant, 
for negligible lZ51 label was detected in the soluble cyto- 
plasmic fraction. 
Scatchard analysis [ 161 of concentration-dependent 
binding data from experiments of the type depicted in 
Fig. 1 indicated that the neonatal rat cardiomyocyte 
displayed one class of specific TGF-P2 binding sites 
with a Kd of -26 pM, a B,,, of 8.8 fmol/106 cardiomy- 
ocytes, and, maximally, 5,290 binding sites/cell (Fig. 
2A). Inherent limitations associated with applying 
Scatchard formulations to equilibrium-binding data 
may generate gross quantitative errors in apparent re- 
ceptor number/affinity [ 151. We therefore evaluated the 
cardiomyocyte TGF-P2 equilibrium-binding data in a 
more rigorous manner by testing their fit to progres- 
sively more complex models using iterative non-linear 
least-squares regression [14]. Although the cardiomy- 
ocyte [‘“51]TGF-P2 binding data were incompatible with 
any multi-site model tested, they did fit a one-site model 
regardless of whether measured (Fig. 2B) or calculated 
(data not shown) non-specific binding had been used to 
derive specific binding. As summarized in Table I, 
Scatchard analysis gave somewhat higher mean Kd. 
B max, and receptor-density values than did the iterative 
analysis. Better fit with less variability was achieved 
when the measured non-specific binding was used in the 
iterative analysis (Table I), likely reflecting a greater 
inherent error in the computed theoretical non-specific 
binding for a ligand such as TGF-P having a tendency 
to adhere to surfaces [17]. 
A Klotz transformation [15] of the concentration- 
dependent binding data in Fig. 2 yielded a Kd of -22 
pM TGF-/I2 (Fig. 3). in good agreement with the Kd 
values from the Scatchard and non-linear least-squares 
regression analyses (cf. Table I). The distribution of 
binding values on either side of the Klotz-plot inflection 
point demonstrated that the [“‘I]TGF-P2 concentration 
range studied adequately bracketed the receptor Kd [15]. 
Picomolar concentrations of unlabeled TGF-P2 effec- 
Table I 
Characterization of the cardiomyocyte TGF-p2 receptor population 
Analysis Receptor parameter 
Best-fit model & 
(vM) 
B rndX Receptor density 
(fmol/lOb cells) (numberlcardromyocyte) 
Scatchard One-sate 26 8.8 5,290 
Non-linear least-squares regression 
Measured non-specific binding One-site 17.3 k 3 4 8.5 + 0.6 5,120 + 480 
Computed non-specific bmding One-site 12.2 f 5.3 6.7 f 1.9 4.030 + 1,023 
Characteristtcs of the cardiomyocyte TGF-,82 receptor population were derived as detailed in Ftg. 2 from concentration-dependent binding data 
obtained in experiments of the type depicted in Fig. 1, Tabulated data are mean values for a typtcal experiment over a3 independent cultures 
(Scatchard analysts) or mean values + S.E.M. (n = 6 independent cultures) (least-squares regresston analysts). 
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Lcx&, FREE ['25 I]TGF-132(M) 
Fig 3. Klotz analysis of cardiomyocyte TGF-p2 binding The total (m) 
and measured non-specific (EI) binding data (Fig. 2) were used to 
generate a semi-logarithmic Klotz transform (- - -). The arrow marks 
the calculated inflection point of the Klotz plot. yleldmg an estimated 
& value of 22 pM 
tively competed for [“51]TGF-P2 specific binding in 
standard incubations with 40 pM [“‘I]TGF-p2 and 
5 x lo5 cardiomyocytes; 50% inhibition of [1’51]TGF-/32 
binding (IC,, value) required 250 pM TGF;02 (Fig. 4). 
In comparison, TGF-,81 weakly competed for 
[“SI]TGF-/?2 binding with an IC,,, of -2 nM. TGF-B3 
was only slightly competitive (IC,, > 10 nM). High (4 
nM) concentrations of unrelated ligands (PDGF, 
aFGF) were not competitive. Specifically bound 
[“51]TGF-/?2 could be rapidly and completely displaced 
by excess unlabeled ligand (Table II). 
In order to visualize the cardiomyocyte TGF-/?2 
binding protein(s), [‘“51]TGF-P2 was cross-linked to cell 
monolayers, and the protein labeling was examined by 
[COMPETITIVE SUBSTANCE] (nM) 
Fig. 4. Competition of cardiomyocyte [“51]TGF-fi2 specific bmdmg by 
unlabeled TGF-PI (o), TGF-b2 (m). TGF$3 (0). PDGF (0). or aFGF 
(A). Specific binding IS expressed relative to that in contemporaneous 
cultures not contaming unlabeled test substance. The data are from 
a representative experiment on 3 independent cultures; the range 
about each mean was ~8%. 
SDS-PAGE followed by autoradiography. The cross- 
linking pattern obtained was similar to that reported for 
other cell types [19] in that it showed three major TGF- 
82 binding proteins (Fig. 5). Most of the [“51]TGF-/?2 
was associated with a -280-kDa complex, probably the 
type III cell surface proteoglycan [19]. Two other bind- 
ing proteins with apparent molecular masses of -55 
kDa and -85 kDa probably correspond to the type I 
and type II receptors, respectively 11,191. SDS-PAGE 
analysis of cell membranes isolated from affinity-la- 
beled cardiomyocytes by hypotonic lysis [ll] gave a 
comparable autoradiographic pattern (data not shown). 
None of these binding proteins became labeled in the 
absence of the cross-linking agent, DSS (data not 
shown). In accord with the biochemical competition 
studies (Fig. 4). [“‘IITGF$2 labeling of these three 
binding proteins was significantly diminished by excess 
unlabeled TGF;02 (Fig. 5A), whereas excess aFGF was 
non-competitive (Fig. 5B). The relatively low cardiomy- 
ocyte TGF;02 receptor density, the pronounced ‘sticki- 
ness’ of this growth factor [17]. and the predominance 
of [“‘I]TGF-P2 binding to the high-molecular weight 
protein obviated absolutely clear ‘background’ lanes 
with excess unlabeled ligand. 
4. DISCUSSION 
TGF-p exerts anti-ischemic cardioprotection by 
mechanisms postulated to involve effects on heart mus- 
cle [5,6]. Although cardiac muscle contains and synthe- 
sizes TGF-,@ [3], the potential of the mammalian cardio- 
myocyte to express specific cell surface TGF-/? receptors 
has not been rigorously and quantitatively examined. 
The present work provides several lines of direct bio- 
chemical evidence demonstrating that the neonatal rat 
cardiomyocyte has a population of specific, high-affin- 
ity sarcolemmal binding proteins for TGF-p2, one of 
the major mammalian isoforms [1.2]. The rapidity. 
saturability. ligand-selectivity, and reversibility of car- 
diomyocyte TGF-/32 specific binding are all consistent 
with a receptor-mediated process. Both Scatchard anal- 
Table II 
Displacement of specifically bound cardlomyocyte [“‘I]TGF$2 
[“51]TGF-j?2 Displacement (% total [“I]TGF-B2 
(PM) speclfically bound) 
0 mm 10 mm 30 mm 60 mm 
4 0 48.2 63.5 91.8 
20 0 87.1 98.5 100.0 
40 0 84.3 97 4 100.0 
Data are mean % loss of specifically bound cardiomyocyte [“‘I]TGF- 
p2 after the labeled cells were incubated with a 1 .OOO-fold molar excess 
of non-radioactive TGF-B2 for the indicated time periods. Values are 
averages ofthree Independent experiments: the range about each mean 
was <IO%. 
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Fig. 5. Affinity labeling of cardiomyocyte TGF-b2 binding proteins. (A) Cardiomyocytes were cross-linked to Increasing concentrations of 
[“51]TGF-p2 in the absence (lanes 1, 3. 5. 7) or presence (lanes 2. 4, 6. 8) of a l.OOO-fold molar excess of unlabeled hgand. (B) Cardiomyocytes 
were cross-linked to 40 pM [“51]TGF-@2 in the absence (lane I) or presence of either a l,OOO-fold molar excess of unlabeled TGF,B2 (lane 2) or 
a 250-fold molar excess of unlabeled aFGF (lane 3). Solubilized cell extracts were subjected to SDS-PAGE on 7% gels, and the dried gels were 
analyzed by autoradiography. Molecular mass markers are Indicated in kDa to the left of each gel series, the locations of putative bmdmg protein 
types I, II. and III are indicated to the right 
ysis [ 161 and computer-assisted non-linear least-squares 
iterative fitting [14] demonstrated that the TGF-P’, 
binding proteins behave as a single class of high-affinity 
(apparent Kd s 26 pM) receptors with -5,000 binding 
sites/cardiomyocyte and an apparent B,,,,, of -9 fmol/ 
lo6 cells. 
While this is the first study to identify and character- 
ize the cardiomyocyte TGF-82 receptor population, 
many other cell types bind TGF-B isoforms with appar- 
ent Kd’s in the pM range [l]. As few as 600 and as many 
as 8 x lo4 TGF-/? binding sites/cell have been reported, 
the highest affinity receptors generally present at the 
lowest densities [1,2]. Thus, the cardiomyocyte TGF-/?2 
receptor population has a capacity and affinity compa- 
rable to TGF-/I receptors in non-muscle cells, albeit 
toward the lower end of the density range. Although 
binding characteristics among the TGF-P isoforms in a 
given cell type may differ, the results of our competition 
experiments (Fig. 4) suggest either that distinct cardio- 
myocyte TGF-j?l and $3 receptor(s) exist or that the 
cardiomyocyte expresses one population of TGF-P 
binding proteins having markedly lower affinities for 
TGF-PI and $3 than for $2. 
Chemical cross-linking of [“‘IITGF-/?2 to cardiomy- 
ocytes allowed provisional molecular identification of 
three discrete TGF-j?2 binding proteins. The affinity- 
labeled cardiomyocyte complexes resemble on SDS- 
PAGE the type I(-55 kDa), type II (-70-U kDa), and 
type III proteoglycan (-250-350 kDa) binding proteins 
detected on many cell types [ 1,191. The type I and type 
II binding proteins act as the signalling receptor in a 
complex with ligand. whereas the role of the proteogly- 
can is a matter of current debate [2]. In the cardiomy- 
ocyte, apparently more [“51]TGF-/?2 became associated 
with the proteoglycan than with the type I and II bind- 
ing proteins (Fig. 5), as has been observed in some other 
cell types [ 181. The presence of high-affinity TGF-b2 
receptors on the mammalian cardiomyocyte makes it 
tempting to speculate that this cytokine family may 
modulate cardiomyocyte physiology by as yet unknown 
receptor-mediated pathways of signal transduction, 
some of which may be cardioprotective. 
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